BEAM vs FULC
BEAM: Beam Therapeutics is developing base editing medicines—a precision genetic cure approach—for serious inherited diseases like sickle cell disease and rare genetic disorders. FULC: Fulcrum Therapeutics discovers and develops treatments for genetically-defined rare diseases, with pociredir as a lead clinical-stage program.
Side-by-side fundamentals
| Metric | BEAM | FULC | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $26.64 | $3.70 | |
| Market cap as of 2026-07-23 | $2.7B | $248M | |
| PEG as of 2026-07-23 | n/a | -0.00 | |
| Net margin as of 2026-07-23 | -39.7% | +8.1% | FULC higher |
| Operating margin as of 2026-07-23 | -226.6% | -3.6% | FULC higher |
| ROE as of 2026-07-23 | -5.9% | -22.5% | BEAM higher |
| ROA as of 2026-07-23 | -4.6% | -21.2% | BEAM higher |
| Debt / equity as of 2026-07-23 | 0.09 | 0.00 | FULC lower |
| Revenue growth (YoY) as of 2026-07-23 | +158.0% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +31.9% | n/a | |
| Beta as of 2026-07-23 | 2.22 | 2.59 | |
| 1-year return as of 2026-07-22 close | +29.8% | -48.2% | BEAM higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.